Association Between Proton Pump Inhibitors and the Risk of Intestinal Behcet Disease

被引：0

作者：

Murakami, Keita ^{[1
]}

Arai, Junya ^{[1
,2
]}

Ihara, Sozaburo ^{[1
]}

Hirata, Yoshihiro ^{[1
,3
]}

Tsuchida, Yumi ^{[4
]}

Shoda, Hirofumi ^{[4
]}

Tsuboi, Mayo ^{[1
]}

Kurokawa, Ken ^{[1
]}

Suzuki, Nobumi ^{[1
]}

Kinoshita, Hiroto ^{[1
]}

Hayakawa, Yoku ^{[1
]}

Fujio, Keishi ^{[4
]}

Fujishiro, Mitsuhiro ^{[1
]}

机构：

[1] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Hongo 7-3-1,Bunkyo Ku, Tokyo 1138655, Japan

[2] Asahi Life Fdn, Inst Med Sci, Dept Gastroenterol, Tokyo, Japan

[3] Univ Tokyo, Inst Med Sci, Div Adv Genome Med, Tokyo, Japan

[4] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan

来源：

JOURNAL OF RHEUMATOLOGY | 2024年 / 51卷 / 12期

基金：

日本学术振兴会;

关键词：

Behcet disease; intestinal diseases; proton pump inhibitors;

D O I：

10.3899/jrheum.2024-0442

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. This study aimed to investigate the association between proton pump inhibitor (PPI) use and the incidence of intestinal Beh & ccedil;et's disease (BD) in patients with BD. Methods. A retrospective cohort study was conducted at the University of Tokyo Hospital, including BD patients diagnosed between April 2005 and November 2023. Cox models and Kaplan-Meier analyses were utilized to evaluate hazard ratios (HRs) and cumulative incidence of intestinal BD, respectively. Secondary analyses were performed to assess the duration and dose-response relationship of PPI use. Results. Among 194 BD patients, 25.3% developed intestinal BD during a mean followup of 12 years. PPI users exhibited a significantly higher incidence of intestinal BD compared to non-users (adjusted HR 2.48, 95% CI 1.38-4.47, P = 0.0024), with a confirmed duration/dose-dependent relationship. The cumulative incidence of intestinal BD was markedly elevated in PPI users (Log rank P < 0.001). The result was similar to that in the Propensity score-matched cohort. Conclusion. The study demonstrates a significant association between PPI use and increased incidence of intestinal BD in BD patients. Caution in prescribing PPIs for BD patients is warranted due to the potential risk of severe complications associated with intestinal BD.

引用

页码：1193 / 1197

页数：5

共 16 条

[11] Yasar Bilge NS, Perez Brocal V, Kasifoglu T, Et al., Intestinal microbiota composition of patients with Behçet’s disease: differences between eye, mucocutaneous and vascular involvement. The Rheuma-BIOTA study, Clin Exp Rheumatol, 38, pp. 60-68, (2020)
[12] Arai J, Kato J, Toda N, Et al., Risk factors of poor prognosis and impairment of activities of daily living in patients with hemorrhagic gastroduodenal ulcers, BMC Gastroenterol, 21, (2021)
[13] Niikura R, Hayakawa Y, Hirata Y, Et al., Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis, Gut, 67, pp. 1908-1910, (2018)
[14] Janarthanan S, Ditah I, Adler DG, Et al., Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis, Am J Gastroenterol, 107, pp. 1001-1010, (2012)
[15] Arai J, Niikura R, Hayakawa Y, Et al., OLGIM staging and proton pump inhibitor use predict the risk of gastric cancer, Gut, 71, pp. 1043-1044, (2022)
[16] Arai J, Niikura R, Hayakawa Y, Et al., Nonsteroidal anti-inflammatory drugs prevent gastric cancer associated with the use of proton pump inhibitors after Helicobacter pylori eradication, JGH Open, 5, pp. 770-777, (2021)

← 1 2 →